🇺🇸 FDA
Pipeline program

GIA632, Placebo to GIA632 150 mg/mL solution for injection

CGIA632A12201

Phase 2 small_molecule active

Quick answer

GIA632, Placebo to GIA632 150 mg/mL solution for injection for Atopic dermatitis is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Atopic dermatitis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials